Association between plasma miRNA-145 levels and number of diseased vessels.

<p>These bars represent averages of plasma miRNA-145 levels among patients with single-, double- and triple-vessel CAD. T-bars indicate standard deviation. Patients with three-vessel disease have significantly lower levels of miRNA-145 compared with the rest of the groups. Levels were not significantly different between patients with single- and double-vessel CAD. * <i>p</i> <0.05; CAD, coronary artery disease, RNA, Ribonucleic acid.</p

Univariate linear regression analysis for plasma levels of Ln_miRNA-145.

<p>* <i>p</i><0.05; Data are expressed as parameter estimates with standard errors. All continuous variables were standardized to a mean of 0 and a standard deviation of 1; all dichotomous variables were coded as 0 = presence and 1 = absence; CAD, Coronary artery disease.</p><p>Univariate linear regression analysis for plasma levels of Ln_miRNA-145.</p

SYNTAX groups and plasma miRNA-145.

<p>These bars represent averages of plasma miRNA-145 levels across SYNTAX groups. T-bars indicate standard deviation. It can be noted that patients with high risk SYNTAX scores had significantly lower Ln_miRNA-145 compared with low and moderate risk groups. * <i>p</i> <0.05; RNA, Ribonucleic acid; SYNTAX, Synergy Between PCI With Taxus and Cardiac Surgery.</p

Plasma miRNA-145 levels and clinical presentation of CAD.

<p>These bars represent averages of Ln_miRNA-145 values among different clinical presentations of CAD compared with non-CAD patients. T-bars indicate standard deviation. Patients with ST-elevation myocardial infarction had significantly lower values of Ln_miRNA-145 compared with the rest of the groups. Non-CAD subjects had significantly higher Ln_miRNA-145 than patients with CAD. * <i>p</i> <0.05; CAD, Coronary artery disease; RNA, Ribonucleic acid.</p

Basic patient characteristics in the whole population.

<p>Continuous data are expressed as mean ± standard deviation or medial with interquartile range; Categorical data are expressed as frequencies; CAD, Coronary artery disease; hsCRP, High sensitivity C-reactive protein; Ln, Logarithmic; LVEDD, Left ventricular end diastolic diameter.</p><p>Basic patient characteristics in the whole population.</p

Association of miRNA-145 with severity of CAD.

<p>* <i>p</i><0.05; CAD, Coronary artery disease; SE, Standard error; STEMI, ST-elevation myocardial infarction; Data are expressed as parameter estimates with standard errors. All continuous variables were standardized to a mean of 0 and a standard deviation of 1; all dichotomous variables were coded as 0 = presence and 1 = absence. Traditional risk factors include age, male gender, body mass index, diabetes, hypertension, dyslipidemia, smoking. SYNTAX groups were represented as continuous values.</p><p>Association of miRNA-145 with severity of CAD.</p

Univariate and multivariate logistic regression analyses of possible factors associated for higher basal transcardiac troponin release (above median: 1.1 pg/mL).

<p>eGFR: estimated glomerular filtration rate, LVEF: left ventricular ejection fraction, LVH: left ventricular hypertrophy.</p

Characteristics of patients who underwent the ACh test.

<p>Data are the mean (standard deviation) or number (percentage).</p>*<p>Median and 25th–75th percentiles. LDL: low-density lipoprotein, HDL: high-density lipoprotein, eGFR: estimated glomerular filtration rate, ACE: angiotensin converting enzyme, ARB: angiotensin II receptor blocker.</p

Transcardiac troponin release of patients with positive or negative ACh tests.

<p>Data are the median (25th–75th percentiles) or number (percentage).</p>*<p>p<0.01 for the comparison with baseline.</p>†<p>p = 0.73 for the comparison with baseline.</p

Transcardiac troponin release before and after the ACh test.

<p>There was a significant increase in transcardiac troponin release after the ACh provocation test in 17 patients with coronary spasms (p<0.01 for the comparison with baseline) but not in 16 patients without spasms (p = 0.73).</p